Interview

Interview with David Mangelsdorf for personalized medicine

Research output: Contribution to journalArticle

Abstract

David Mangelsdorf is Professor and Chair of Pharmacology at the University of Texas Southwestern Medical Center in Dallas (TX, USA) where he holds the Beatrice and Miguel Elias Distinguished Chair in Biomedical Science and the Distinguished Chair in Pharmacology. He received his BSc in biology and chemistry from Northern Arizona University (AZ, USA) in 1981 and his PhD in biochemistry from the University of Arizona (AZ, USA) in 1987. He did his postdoctoral studies at The Salk Institute for Biological Studies (CA, USA; 1987-1993). David Mangelsdorf has also been an Investigator of the Howard Hughes Medical Institute (MD, USA) since moving to Dallas in 1993. His current research focuses on understanding the molecular basis of transcriptional signaling by nuclear hormone receptors and exploiting their ligand dependency to discover novel therapeutic options for fighting diseases such as atherosclerosis, gallstone disease, cholestasis, metabolic syndrome, cancer and infectious parasitic diseases. His research team recently discovered a correlation between the expression of two nuclear receptor proteins in non-small-cell lung cancer tissue samples with patients clinical outcomes. The research features in PLoS Medicine and suggests that the nuclear receptor proteins could serve as therapeutic targets in non-small-cell lung cancer.

Original languageEnglish (US)
Pages (from-to)513-516
Number of pages4
JournalPersonalized Medicine
Volume8
Issue number5
DOIs
StatePublished - Sep 2011

Fingerprint

Precision Medicine
Cytoplasmic and Nuclear Receptors
Interviews
Nuclear Proteins
Non-Small Cell Lung Carcinoma
Research
Pharmacology
Parasitic Diseases
Cholestasis
Metabolic Diseases
Gallstones
Biochemistry
Communicable Diseases
Atherosclerosis
Research Personnel
Medicine
Ligands
Therapeutics
Neoplasms

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology
  • Medicine(all)

Cite this

Interview : Interview with David Mangelsdorf for personalized medicine. / Mangelsdorf, David.

In: Personalized Medicine, Vol. 8, No. 5, 09.2011, p. 513-516.

Research output: Contribution to journalArticle

@article{b30da601f0434816bf241a74705baafe,
title = "Interview: Interview with David Mangelsdorf for personalized medicine",
abstract = "David Mangelsdorf is Professor and Chair of Pharmacology at the University of Texas Southwestern Medical Center in Dallas (TX, USA) where he holds the Beatrice and Miguel Elias Distinguished Chair in Biomedical Science and the Distinguished Chair in Pharmacology. He received his BSc in biology and chemistry from Northern Arizona University (AZ, USA) in 1981 and his PhD in biochemistry from the University of Arizona (AZ, USA) in 1987. He did his postdoctoral studies at The Salk Institute for Biological Studies (CA, USA; 1987-1993). David Mangelsdorf has also been an Investigator of the Howard Hughes Medical Institute (MD, USA) since moving to Dallas in 1993. His current research focuses on understanding the molecular basis of transcriptional signaling by nuclear hormone receptors and exploiting their ligand dependency to discover novel therapeutic options for fighting diseases such as atherosclerosis, gallstone disease, cholestasis, metabolic syndrome, cancer and infectious parasitic diseases. His research team recently discovered a correlation between the expression of two nuclear receptor proteins in non-small-cell lung cancer tissue samples with patients clinical outcomes. The research features in PLoS Medicine and suggests that the nuclear receptor proteins could serve as therapeutic targets in non-small-cell lung cancer.",
author = "David Mangelsdorf",
year = "2011",
month = "9",
doi = "10.2217/pme.11.45",
language = "English (US)",
volume = "8",
pages = "513--516",
journal = "Personalized Medicine",
issn = "1741-0541",
publisher = "Future Medicine Ltd.",
number = "5",

}

TY - JOUR

T1 - Interview

T2 - Interview with David Mangelsdorf for personalized medicine

AU - Mangelsdorf, David

PY - 2011/9

Y1 - 2011/9

N2 - David Mangelsdorf is Professor and Chair of Pharmacology at the University of Texas Southwestern Medical Center in Dallas (TX, USA) where he holds the Beatrice and Miguel Elias Distinguished Chair in Biomedical Science and the Distinguished Chair in Pharmacology. He received his BSc in biology and chemistry from Northern Arizona University (AZ, USA) in 1981 and his PhD in biochemistry from the University of Arizona (AZ, USA) in 1987. He did his postdoctoral studies at The Salk Institute for Biological Studies (CA, USA; 1987-1993). David Mangelsdorf has also been an Investigator of the Howard Hughes Medical Institute (MD, USA) since moving to Dallas in 1993. His current research focuses on understanding the molecular basis of transcriptional signaling by nuclear hormone receptors and exploiting their ligand dependency to discover novel therapeutic options for fighting diseases such as atherosclerosis, gallstone disease, cholestasis, metabolic syndrome, cancer and infectious parasitic diseases. His research team recently discovered a correlation between the expression of two nuclear receptor proteins in non-small-cell lung cancer tissue samples with patients clinical outcomes. The research features in PLoS Medicine and suggests that the nuclear receptor proteins could serve as therapeutic targets in non-small-cell lung cancer.

AB - David Mangelsdorf is Professor and Chair of Pharmacology at the University of Texas Southwestern Medical Center in Dallas (TX, USA) where he holds the Beatrice and Miguel Elias Distinguished Chair in Biomedical Science and the Distinguished Chair in Pharmacology. He received his BSc in biology and chemistry from Northern Arizona University (AZ, USA) in 1981 and his PhD in biochemistry from the University of Arizona (AZ, USA) in 1987. He did his postdoctoral studies at The Salk Institute for Biological Studies (CA, USA; 1987-1993). David Mangelsdorf has also been an Investigator of the Howard Hughes Medical Institute (MD, USA) since moving to Dallas in 1993. His current research focuses on understanding the molecular basis of transcriptional signaling by nuclear hormone receptors and exploiting their ligand dependency to discover novel therapeutic options for fighting diseases such as atherosclerosis, gallstone disease, cholestasis, metabolic syndrome, cancer and infectious parasitic diseases. His research team recently discovered a correlation between the expression of two nuclear receptor proteins in non-small-cell lung cancer tissue samples with patients clinical outcomes. The research features in PLoS Medicine and suggests that the nuclear receptor proteins could serve as therapeutic targets in non-small-cell lung cancer.

UR - http://www.scopus.com/inward/record.url?scp=80052717582&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052717582&partnerID=8YFLogxK

U2 - 10.2217/pme.11.45

DO - 10.2217/pme.11.45

M3 - Article

VL - 8

SP - 513

EP - 516

JO - Personalized Medicine

JF - Personalized Medicine

SN - 1741-0541

IS - 5

ER -